Home / Markets / News / Thyrocare Technologies shares fall 7% on Q3 results; check key numbers here

Thyrocare Technologies shares fall 7% on Q3 results; check key numbers here

Thyrocare reported a strong performance for the Q3FY26, with consolidated profit after tax (PAT) after exceptional items rising 80 per cent to ₹34.07 crore from ₹18.94 crore in the year-ago period

Thyrocare Technologies

2 min read Last Updated : Jan 29 2026 | 11:44 AM IST

Listen to This Article

Thyrocare Technologies share price today: Shares of healthcare diagnostics company Thyrocare Technologies fell over 7 per cent to hit an intraday low of ₹423 on the National Stock Exchange (NSE) after the company reported its results for the October to December quarter of fiscal 2026 (Q3FY26).

Around 11:00 AM, the company's share price was trading 7 per cent lower at ₹426.5 compared to the previous session's close of ₹458.7 on the NSE. In comparison, the NSE Nifty50 was down 0.4 per cent at 25,240 levels. The market capitalisation of the company stood at ₹6,831 crore. The stock has fallen around 20 per cent from the 52-week high of ₹536.67 touched on November 18, 2025.

Thyrocare Technologies Q3 results

Thyrocare reported a strong performance for the Q3FY26, with consolidated profit after tax (PAT) after exceptional items rising 80 per cent to ₹34.07 crore from ₹18.94 crore in the year-ago period.

The company's consolidated revenue from operations jumped 18 per cent year-on-year (Y-o-Y) to ₹195.53 crore in Q3FY26 compared to ₹165.92 crore in Q3FY25. On a standalone basis, the company's revenue increased 20 per cent Y-o-Y to ₹183 crore. The growth was led by continued momentum in the Pathology business, which grew 20 per cent Y-o-Y.

Earnings before interest, tax, depreciation and amortisation (Ebitda) stood at ₹57.64 crore, up 38 per cent from ₹41.64 crore.

Also Read

Stock Market LIVE: Sensex slips 280 pts; Nifty near 25,250; Hindustan Copper up 16%, L&T 3%

SBI Life Insurance share price target, q3 results

SBI Life slips 3% post Q3; Street flags GST impact, sees margin recovery

Just a day ahead of the hurriedly called Vodafone Idea (Vi) meeting meant to soothe the nerves of investors amid the company's sliding stock price and a negative narrative around it, the telco announced a $3.6-billion (Rs 30,000 crore) deal with glob

Vodafone Idea unveils ₹45k-cr revival plan; analysts cautious on execution

Piramal Pharma shares gain 4% on Q3 results; check key highlights inside

Lodha Developers shares rise as Q3 profit comes in line with estimates

The company's franchisee revenue grew 12 per cent Y-o-Y to ₹112 crore, and partnership revenue increased 39 per cent Y-o-Y to ₹60 crore. Its active franchisee count increased 12 per cent Y-o-Y to 10,300. It processed around 49.6 million tests in the quarter under review, up 22 per cent from the year-ago period.

For the nine months ended December 31, 2025, Thyrocare reported a PAT of ₹120.03 crore, compared with ₹68.65 crore in the year-ago period, while revenue rose to ₹605.09 crore from ₹500.19 crore last year.

Thyrocare Technologies is a fully automated laboratory chain with a presence across India. It offers diagnostic services to laboratories and hospitals. It is one of the first Indian diagnostic laboratories to obtain internationally renowned quality accreditations, including ISO 9001-2000 rating as early as 2001.